Phase 2 Study of Gemzar, Taxol & Avastin Combination as 1st Line Treatment for Metastatic Breast Cancer

Part of paid clinical trials in Stanford, California.

Sponsor
George Albert Fisher
Study ID
NCT00403130
Phase
PHASE2
Status
Completed

Conditions

Eligibility Criteria

Sex
FEMALE
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Gemcitabine — DRUG
    Gemcitabine 1000 mg/m2 by IV infusion, days 1, 8, and 15 in 28-day cycles
  • Paclitaxel — DRUG
    Paclitaxel 80 mg/m2 by IV infusion, days 1, 8, and 15 in 28-day cycles
  • Bevacizumab — DRUG
    Bevacizumab 10 mg/kg by IV infusion, days 1 and 15 in 28-day cycles

Study Details

Single-institution phase 2 trial investigating the efficacy of capecitabine, oxaliplatin and bevacizumab for patients with metastatic neuroendocrine tumors.

Key Dates

First listed
Nov 23, 2006
Start date
Feb 28, 2006
Status verified
Jan 2019
Primary completion
Sep 30, 2010
Completion
Nov 30, 2012

Study Design

Enrollment
31 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Phase II 3-drug regimen
    Gemcitabine + Paclitaxel + Bevacizumab

Primary Outcome Measure

Time-to-Progression (TTP) [ Time Frame: 2 years ]

Locations (1)

FacilityCityStateZIPSite coordinators
Stanford University School of MedicineStanfordCalifornia94305-

Find similar trials in Stanford, CA

By condition
Breast cancer
By specialty
OncologyBreast oncologyWomen's health
By research site
Stanford University School of Medicine· Stanford, CA

Related Studies